Scientists have created a modified version of an antibody that can precisely target a protein involved in cancer growth and spread. The original antibody was derived from a mouse, but the new version has been “humanized” to potentially reduce the risk of triggering an immune response in patients. This humanized antibody binds to the same target as the original, and molecular modeling suggests how it interacts at the molecular level. This research could lead to new, more targeted treatments that can prevent cancer from spreading.
Funding
Funding was provided by Mid-Career Research Grant, SUT Full-time Doctoral Research, the Thailand Science Research and Innovation (TSRI), Grant for a New Researcher Career Path, the Visiting Professor Grant from Chiang Mai University, Thailand, the Distinguished Research Professor Grant of the National Research Council of Thailand, the Office of National Higher Education Science Research and Innovation Policy Council (NXPO), Thailand, through Program Management Unit for Competitiveness (PMU C), the Program Management Unit for Human Resources and Institutional Development, Research and Innovation, the Permanent Secretary, Ministry of Higher Education, Science, Research and Innovation, and Fundamental Fund 2022, Chiang Mai University.
Original Paper
Title of original paper: Immunoreactivity of humanized single-chain variable fragment against its functional epitope on domain 1 of CD147
Journal: Scientific Reports
DOI: https://doi.org/10.1038/s41598-022-10657-3